Pfizer - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Pfizer

Top of Directory » All Categories » by Company » Pfizer



  • A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Patch Applied To The Skin

    Condition:   Smoking Cessation
    Intervention:   Drug: varenicline free base patch
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

    Condition:   Healthy Volunteers
    Interventions:   Drug: PF-04531083 or Placebo;   Drug: PF-04531083 or Placebo;   Drug: PF-04531083 or Placebo;   Drug: PF-04531083 or Placebo
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously And Subcutaneously To Healthy Adult Volunteers

    Condition:   Healthy Volunteers
    Interventions:   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429;   Drug: PF-04427429
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom

    Conditions:   Glaucoma;   Ocular Hypertension
    Intervention:   Other: no intervention
    Sponsor:   Pfizer
    Completed - verified November 2009
  • An Investigation of the Absorption and Pharmacokinetics of Multiple Doses of Three Controlled Release Pregabalin Tablets as Compared to Multiple Doses of the Immediate Release Pregabalin Capsule

    Condition:   Healthy
    Interventions:   Drug: Pregabalin controlled release, 82.5 mg;   Drug: Pregabalin controlled release, 165 mg;   Drug: Pregabalin controlled release, 330 mg;   Drug: Pregabalin immediate release, 150 mg
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • Caverject User Study

    Condition:   Erectile Dysfunction
    Intervention:   Other: delivery system
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

    Condition:   Advanced Solid Tumors
    Interventions:   Drug: PF-01367338;   Drug: Carboplatin;   Drug: PF-01367338;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: PF-01367338;   Drug: Cisplatin;   Drug: Pemetrexed
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • Azithromycin in Bronchiolitis Obliterans Syndrome

    Conditions:   Bronchiolitis Obliterans Syndrome;   Graft Rejection;   Lymphocytic Bronchiolitis;   Respiratory Infection
    Interventions:   Drug: Azithromycin;   Drug: Placebo
    Sponsors:   Katholieke Universiteit Leuven;   University Hospital, Gasthuisberg;   Fund for Scientific Research, Flanders, Belgium
    Active, not recruiting - verified November 2009
  • Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

    Conditions:   HIV-1 Adults Patients;   AIDS;   Triple Class Failure
    Interventions:   Drug: maraviroc;   Drug: Raltegravir;   Drug: Darunavir/ritonavir
    Sponsors:   The Huesped Foundation;   Pfizer
    Not yet recruiting - verified November 2009
  • A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

    Conditions:   Excessive Daytime Sleepiness;   Narcolepsy
    Interventions:   Drug: Placebo;   Drug: PF-03654746
    Sponsor:   Pfizer
    Recruiting - verified November 2009
  • Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers

    Condition:   Alzheimer's Disease
    Interventions:   Biological: PF-04360365;   Drug: Placebo
    Sponsor:   Pfizer
    Not yet recruiting - verified October 2009
  • A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

    Condition:   Advanced Solid Tumors
    Interventions:   Drug: CVX-241;   Drug: CVX-241;   Drug: CVX-241;   Drug: CVX-241;   Drug: CVX-241;   Drug: CVX-241
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet

    Condition:   Healthy Volunteers
    Interventions:   Drug: Amlodipine;   Drug: Amlodipine;   Drug: Amlodipine;   Drug: Amlodipine
    Sponsor:   Pfizer
    Not yet recruiting - verified October 2009
  • A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers

    Condition:   Healthy
    Interventions:   Drug: PF-04418948;   Drug: PF-04418948;   Drug: PF-04418948;   Drug: PF-04418948;   Drug: PF-04418948;   Drug: PF-04418948;   Drug: PF-04418948
    Sponsor:   Pfizer
    Recruiting - verified October 2009
  • Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

    Conditions:   Age-Related Maculopathy;   Age-Related Maculopathies;   Eye Diseases;   Retinal Degeneration;   Macular Degeneration
    Interventions:   Biological: RN6G;   Biological: Placebo
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

    Condition:   Prostatic Hyperplasia
    Intervention:   Drug: Doxazosin mesylate GITS
    Sponsor:   Pfizer
    Not yet recruiting - verified October 2009
  • A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

    Conditions:   Sleep;   Healthy Volunteers
    Interventions:   Drug: PF-04457845 / matched placebo;   Drug: PF-04457845 / matched placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009
  • Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

    Conditions:   Smoking Cessation;   Bipolar Disorder
    Interventions:   Drug: Varenicline (Chantix);   Drug: Placebo
    Sponsors:   University of Pittsburgh;   National Institute of Mental Health (NIMH);   Pfizer
    Not yet recruiting - verified November 2009
  • Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma

    Conditions:   Hepatocellular Carcinoma;   Hepatitis C Virus Chronic Infection
    Intervention:   Biological: CP 675,206
    Sponsors:   Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra;   Pfizer
    Recruiting - verified November 2009
  • Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

    Conditions:   Intraocular Melanoma;   Melanoma (Skin)
    Interventions:   Drug: sunitinib malate;   Drug: temozolomide
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified October 2009
  • Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

    Condition:   Schizophrenia
    Intervention:   Drug: Ziprasidone
    Sponsors:   The University of North Carolina, Chapel Hill;   Pfizer;   National Institute of Mental Health (NIMH)
    Completed - verified November 2009
  • PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer

    Condition:   Lung Cancer
    Interventions:   Drug: PF-00299804;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
    Sponsor:   NCIC Clinical Trials Group
    Not yet recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials